Direkt zum Inhalt
Merck

Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques (2014-09-17)
Loqman A Mohamed, Amal Kaddoumi
ZUSAMMENFASSUNG

PURPOSE. The knowledge of hepatic disposition kinetics of tacrine, a first cholinesterase inhibitor was approved by FDA for the treatment of Alzheimer's disease (AD), would help to understand its hepatotoxicity, its therapeutic effect, and improve the management of patients with AD. The current study aims to characterize tacrine hepatic transport kinetics and study the role of organic cation transporters (OCTs), P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP2) in tacrine sinusoidal uptake and biliary excretion. METHODS. Modulation of tacrine hepatic uptake and efflux, biliary excretion index (BEI%), were performed in sandwich-cultured primary rat hepatocytes (SCHs) using transporters inhibitors. Conformation of the integrity of SCHs model was established by capturing images with light-contrast and fluorescence microscopy. RESULTS. Tacrine uptake in SCHs was carrier-mediated process and saturable with apparent Km of 31.5±9.6 µM and Vmax of 908±72 pmol/min/mg protein. Tetraethyl ammonium (TEA), cimetidine and verapamil significantly reduced tacrine uptake with more pronounced effect observed with verapamil which caused 3-fold reduction in tacrine uptake, indicating role for OCTs. Tacrine has a biliary excretion in SCHs with maximum BEI% value of 22.9±1.9% at 10 min of incubation. Addition of MK571 and valspodar decreased the BEI% of tacrine by 40 and 60% suggesting roles for canalicular MRP2 and P-gp, respectively. CONCLUSIONS. Our results show that in addition to metabolism, tacrine hepatic disposition is carrier-mediated process mediated by sinusoidal OCTs, and canalicular MRP2 and P-gp.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Tetraethylammoniumchlorid, ≥98% (titration)
Sigma-Aldrich
(±)-Verapamil -hydrochlorid, ≥99% (titration), powder
Sigma-Aldrich
Selensäure, 98%
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
USP
Verapamil -hydrochlorid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
9-Amino-1,2,3,4-Tetrahydroacridin -hydrochlorid Hydrat, ≥99%
Sigma-Aldrich
Tetraethylammoniumchlorid, BioUltra, for molecular biology, ≥99.0% (AT)
Sigma-Aldrich
Fluvoxamin-Maleat, solid
Sigma-Aldrich
Selensäure, 99.999% trace metals basis
USP
Fluvoxaminmaleat, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Sigma-Aldrich
9-Amino-1,2,3,4-Tetrahydroacridin -hydrochlorid Hydrat, ≥99%
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Verapamilhydrochlorid, European Pharmacopoeia (EP) Reference Standard
Supelco
(±)-Verapamil -hydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Tetraethylammoniumchlorid, for electrochemical analysis, ≥99.0%
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Supelco
Dexamethason, VETRANAL®, analytical standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Dexamethason, British Pharmacopoeia (BP) Assay Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Fluvoxamin-Maleat, European Pharmacopoeia (EP) Reference Standard
Fluvoxamin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard